Prognostic and diagnostic significance of serum p53 antibody levels in patients with surgically treated pancreatic cancer

Serum p53 antibody (s-p53-Ab) levels increase in patients with various cancer types; however, their clinicopathological relevance in pancreatic ductal adenocarcinoma (PDAC) is not well defined.The present study aimed to assess the prognostic value of s-p53-Ab status in PDAC.The present retrospective study included 124 patients who underwent surgery for PDAC between January 2012 and December 2023.Patients were categorized into s-p53-Ab(+) and s-p53-Ab(-) groups using a cutoff value of 1.3 U/ml.Prognostic significance was examined using univariate and multivariate analyses.A total of 25 patients (20%) were s-p53-Ab-positive.The isolated s-p53-Ab positivity rates in stage I and II disease were 10 and 8%, respectively.The s-p53-Ab(+) group exhibited significantly worse overall survival (P= 0.038) and relapse-free survival (P= 0.037) than the s-p53-Ab(-) group.Multivariate analysis revealed that s-p53-Ab(+) independently predicted poorer relapse-free survival (P= 0.044) and overall survival (P= 0.048).s-p53-Ab was occasionally positive in stage I/II PDAC and was associated with more aggressive disease behavior.The present study was registered as a clinical trial in the University Hospital Medical